The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•11 June 2026•

2 min read

Enliven Therapeutics Reports Positive ELVN-001 Data, Aligns with FDA on Phase 3

Key Facts

1Enliven Therapeutics reported a 61% Major Molecular Response (MMR) in its Phase 1 trial of ELVN-001 for chronic myeloid leukemia.

2The company aligned with the FDA on the 80 mg QD dose and Phase 3 trial design, with initiation expected in H2 2026.

In a move that strengthens hopes for developing next-generation leukemia treatments, Enliven Therapeutics announced promising clinical trial results. The company reported a 61% Major Molecular Response (MMR) in its Phase 1 trial of ELVN-001 for chronic myeloid leukemia. Furthermore, the company has aligned with the U.S. Food and Drug Administration (FDA) on the design for its Phase 3 pivotal trial, which is slated to commence in the second half of 2026.

This progress comes amid intense competition in the biotech sector to develop safer and more effective therapies, with Enliven competing against majors like Novartis and its drug Scemblix. Per market data, the success of the Phase 1 trial at an 80 mg QD dose bolsters the company's competitive standing, particularly as results showed a favorable safety profile in heavily pre-treated patients. Analysts suggest that early FDA alignment significantly de-risks the regulatory path forward into late-stage development.

Investors should watch ELVN stock levels, which closed at $37.00 (close June 10, 2026), to gauge the market's reaction to these results. Looking at the economic calendar, while there are no direct healthcare sector events in the coming days, the Fed Bowman Speech on June 4, 2026, reflects the ongoing focus on financing costs that impact high-growth biotech firms. The timeline for the Phase 3 initiation in late 2026 remains the primary catalyst to watch.